“PrEP reimbursement important for at-risk individuals with limited access to prevention due to cost”

2023-06-13 17:16:46

Pre-exposure prophylaxis (PrEP) for HIV-negative people, emtricitabine and tenofovir disoproxil, has recently been reimbursable. This was established by the Italian Medicines Agency (Aifa) at the request of Mylan Pharmaceuticals Limited. This was discussed at the press conference organized by the Viatris group, of which Mylan is a part, dedicated to the issues of preventing the spread of HIV infection.